Gland Pharma Ltd

Based on the information on pages 9 to 16 of the document "1274812.pdf": - There is no explicit mention of any current or planned fundraising through debt or equity. - The company plans to invest approximately INR 2,000 crores over the next 5 years for capacity expansion, including Brownfield expansions, new BFS line, and ophthalmic line. - Capex for next year is expected to be over INR 400 crores, funded internally based on asset turns of more than 3x. - No discussions or announcements related to issuing new equity or raising debt were stated during the periods covered. - The company's hurdle rate for investments is 20% IRR, reflecting internal funding discipline. Hence, no clear indication of new fundraising through debt or equity is reported in the current discussions.

- Planned capex of approximately INR 2,000 crores over the next 5 years focused on: - Brownfield expansions including new lines, lyophilizers, and additional warehouse capacity. - Investment in BFS (Blow-Fill-Seal) technology lines. - New ophthalmic line with suspension capability. - Capex towards CDMO contracts. - Next year capex expected to be more than INR 400 crores. - Asset turn targeted at more than 3x due to high-value business expectations. - Expansion driven by: - Increased demand and expected growth. - Current capacity constraints in lyophilizers and ophthalmic products. - Need to stay ahead in emerging technology platforms (BFS). - Capex supports base business growth, a strong pipeline of CDMO contracts, and development of complex, differentiated, and higher-value products. - Aim is to maintain strong ROCE, cash generation, and efficient working capital management.

- Company expects overall growth of 12%-13% as a minimum confidence level for FY '27 base business. - Mid-teens growth (around 15%) guidance remains, contingent on product launches and regulatory approvals, especially for Dalba in the U.S. - Dalba is approved in 6 European countries and launched in December; U.S. approval expected in February, pending additional data submission. - Additional demand from Europe expected to offset potential shortfalls in the U.S. Dalba launch. - Cenexi shows strong momentum with 14%-21% revenue growth in FY ’26 and plans capacity expansions; aiming to maintain positive EBITDA and medium- to long-term growth. - Capacity constraints in lyophilizers and liquid vials likely within 1-1.5 years, with ongoing investments to support volume growth. - Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value growth. - Faster CMS approvals in Europe expected to further boost growth beyond 12%-13%.

- Gland Pharma targets a 15% organic CAGR over the next 5 years for base business growth. - Revenue growth driven by upcoming product launches, CDMO contract ramp-ups, and new capacities. - Cartridge fill and finish capacity to expand significantly from 40 million to 140 million units, supporting volume growth. - EBITDA growth supported by cost efficiency initiatives, operating leverage, and synergy benefits (e.g., from Cenexi). - Cenexi is on a turnaround path, with positive EBITDA trends expected to sustain and improve its contribution. - Investment of INR 2,000 crores over 5 years for capacity expansions (including ophthalmic, BFS, vial, lyo, and suspension lines) aimed at high-value, high-turn businesses. - Hurdle rate for new investments is approximately 20% IRR, indicating disciplined capital allocation. - CDMO and GLP-1 business expected to scale up, enhancing future profitability and utilization. - ESOP costs may vary but are expected to decrease for current grants in the near term.

- Gland Pharma is experiencing higher volumes in the U.S., about 19% year-on-year increase, driven by new contracts signed, including GPO contracts. - The company is in discussions with insulin manufacturers for significant orders to utilize the 40 million capacity pen cartridge line. - For the new 100 million capacity line, expected to be ready by Q2 after validation, the existing signed contracts are sufficient to fill the capacity. - There's a focus on CDMO contracts with commercial quantities and take-or-pay agreements, indicating clear revenue visibility over 2-3 years. - Cenexi's annualized revenue is around EUR 200 million, with positive EBITDA expected going forward. - Dalba product launch has been approved in 6 European countries, with U.S. approval pending, potentially adding to orders. - Additional demand from Europe may offset potential U.S. approval delays, indicating a healthy pending orderbook.